Review
Oncology
Kritika Srinivasan Rajsri, Nainita Roy, Sohini Chakraborty
Summary: Acute myeloid leukemia (AML) is a blood cancer characterized by immature blood cells called leukemic blasts. Leukemia stem cells (LSCs) are resistant to chemotherapy and can cause disease relapse. Understanding the molecular basis of LSCs is important in identifying and targeting these cells for more effective treatment.
Article
Oncology
Fu-Jia Liu, Wen-Yan Cheng, Xiao-Jing Lin, Shi-Yang Wang, Tian-Yi Jiang, Ting-Ting Ma, Yong-Mei Zhu, Yang Shen
Summary: This study demonstrated that the combination of MFC MRD and molecular MRD can establish prognostic value in AML patients with specific genetic lesions. After two cycles of consolidation, MFC MRD showed independent predictive significance for clinical outcomes, highlighting the importance of integrating different MRD assessment methods based on genetic characteristics of AML.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Lisa Weijler, Florian Kowarsch, Matthias Woedlinger, Michael Reiter, Margarita Maurer-Granofszky, Angela Schumich, Michael N. Dworzak
Summary: Acute myeloid leukemia (AML) is the second most common and aggressive type of leukemia in children and adolescents. Flow cytometry is an effective method to monitor the number of remaining leukemic cells in the bone marrow of AML patients, but the data patterns are complex and difficult to identify. An automatic assessment approach using a semi-supervised machine learning model has been developed to address these challenges.
Article
Oncology
Francesco Buccisano, Raffaele Palmieri, Alfonso Piciocchi, Luca Maurillo, Maria Ilaria Del Principe, Giovangiacinto Paterno, Stefano Soddu, Raffaella Cerretti, Gottardo De Angelis, Benedetta Mariotti, Maria Antonietta Irno Consalvo, Consuelo Conti, Daniela Fraboni, Mariadomenica Divona, Tiziana Ottone, Serena Lavorgna, Paola Panetta, Maria Teresa Voso, William Arcese, Adriano Venditti
Summary: Upfront genetics/cytogenetics and minimal measurable disease (MRD) are important biomarkers in post-remission transplant allocation in AML. The evolution of transplantation policy over a 20-year period showed a shift towards MRD-driven transplant allocation strategy which resulted in improved overall and disease-free survival, particularly for intermediate-risk patients. High-risk patients received allogeneic transplant while MRD status guided transplant decisions for intermediate and low-risk patients.
Article
Hematology
Fabio Guolo, Carmen Di Grazia, Paola Minetto, Anna Maria Raiola, Marino Clavio, Maurizio Miglino, Elisabetta Tedone, Paola Contini, Rosa Mangerini, Annalisa Kunkl, Nicoletta Colombo, Girolamo Pugliese, Enrico Carminati, Riccardo Marcolin, Monica Passannante, Samuele Bagnasco, Federica Galaverna, Teresa Lamparelli, Filippo Ballerini, Antonia Cagnetta, Michele Cea, Marco Gobbi, Andrea Bacigalupo, Roberto Massimo Lemoli, Emanuele Angelucci
Summary: The study highlighted the importance of pretransplant MRD evaluation combined with transplant-related factors in identifying AML patients at higher risk for relapse. This combined approach may help in defining a more effective overall transplant strategy.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2021)
Review
Oncology
Marisa J. L. Aitken, Farhad Ravandi, Keyur P. Patel, Nicholas J. Short
Summary: Quantification of measurable residual disease (MRD) provides critical prognostic information in acute myeloid leukemia (AML), with different detection platforms having varying sensitivity and applicability. MRD negativity is associated with reduced risk of relapse in AML, but the therapeutic implications remain unclear and require further investigation.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Article
Oncology
Thomas Cluzeau, Roberto M. Lemoli, James McCloskey, Todd Cooper
Summary: Assessment of measurable residual disease (MRD) is important in predicting outcomes and managing high-risk acute myeloid leukemia (AML). However, there is currently no consensus on the best method for determining MRD negativity, making comparisons across studies difficult.
Article
Oncology
Claudia Nunez-Torron Stock, Carlos Jimenez Chillon, Fernando Martin Moro, Juan Marquet Palomanes, Kyra Velazquez Kennedy, Miguel Piris Villaespesa, Ernesto Roldan Santiago, Eulalia Rodriguez Martin, Anabelle Chinea Rodriguez, Valentin Garcia Gutierrez, Gemma Moreno Jimenez, Javier Lopez Jimenez, Pilar Herrera Puente
Summary: Secondary acute myeloid leukemia (s-AML) patients who undergo allogeneic stem-cell transplant (HSCT) have worse survival compared to de novo AML patients, particularly in those who achieve complete remission (CR) before transplant. Factors contributing to the poorer prognosis include an increased risk of relapse and non-relapse mortality. However, patients receiving MAC conditioning had comparable outcomes, regardless of leukemia ontogeny.
HEMATOLOGICAL ONCOLOGY
(2023)
Review
Medical Laboratory Technology
Jingjing Zhang, Jean Oak
Summary: Measurable/minimal residual disease (MRD) tracking is a powerful tool for assessing treatment response and predicting outcomes in acute leukemia. However, clinical and technological challenges need to be addressed to improve its utility in routine patient care.
SEMINARS IN DIAGNOSTIC PATHOLOGY
(2023)
Editorial Material
Oncology
Tali Azenkot, Brian A. Jonas
Summary: Measurable residual disease (MRD) has become a primary marker of risk severity and prognosis in acute myeloid leukemia (AML). However, there is ongoing debate about the monitoring and treatment based on MRD. The identified literature has described the prognostic value of pre-transplant MRD and suggested optimal timing and techniques to quantify MRD. Several studies have addressed the implications of MRD on treatment selection and hematopoietic stem cell transplant, but more prospective, randomized studies are needed to guide the application of MRD in AML treatment, particularly in transplantation.
Article
Multidisciplinary Sciences
Youjin Wang, Weiyin Zhou, Lisa J. McReynolds, Hormuzd A. Katki, Elizabeth A. Griffiths, Swapna Thota, Mitchell J. Machiela, Meredith Yeager, Philip McCarthy, Marcelo Pasquini, Junke Wang, Ezgi Karaesmen, Abbas Rizvi, Leah Preus, Hancong Tang, Yiwen Wang, Loreall Pooler, Xin Sheng, Christopher A. Haiman, David Van Den Berg, Stephen R. Spellman, Tao Wang, Michelle Kuxhausen, Stephen J. Chanock, Stephanie J. Lee, Theresa E. Hahn, Lara E. Sucheston-Campbell, Shahinaz M. Gadalla
Summary: Chromosomal aberrations in pre-HCT peripheral blood of AML patients were analyzed to identify predictors of survival post-transplant. CNLOH in chr17p for CR patients and chr13q for non-CR patients were associated with poor outcomes, with three-fold increased mortality risk even after adjusting for clinical factors. Pre-transplant CNLOH in chr13q or chr17p could be used as a predictor of poor outcomes in AML patients undergoing unrelated donor HCT, warranting further large prospective studies for validation and potential treatment strategies.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Eduardo Ramos Elbal, Jose Luis Fuster, Jose Antonio Campillo, Ana Maria Galera, Mar Bermudez Cortes, Maria Esther Llinares, Irene Jimenez, Mercedes Plaza, Helios Martinez Banaclocha, Jose Antonio Galian, Miguel Blanquer Blanquer, Maria Victoria Martinez Sanchez, Manuel Muro, Alfredo Minguela
Summary: In this study, three MRD monitoring methods (MFC, FISH, and PCR) were used to anticipate relapse of childhood AML. However, preemptive therapies were not effective in preventing disease progression. Therefore, more sensitive MRD monitoring methods and more effective preemptive therapies are needed.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2023)
Article
Oncology
Jesse M. Tettero, Waleed K. W. Al-Badri, Lok Lam Ngai, Costa Bachas, Dimitri A. Breems, Catharina H. M. J. van Elssen, Thomas Fischer, Bjorn T. Gjertsen, Gwendolyn N. Y. van Gorkom, Patrycja Gradowska, Marjolein J. E. Greuter, Laimonas Griskevicius, Gunnar Juliusson, Johan Maertens, Markus G. Manz, Thomas Pabst, Jakob Passweg, Kimmo Porkka, Bob Loewenberg, Gert J. Ossenkoppele, Jeroen J. W. M. Janssen, Jacqueline Cloos
Summary: Measurable residual disease (MRD) measured using multiparameter flow-cytometry (MFC) has significant prognostic value in acute myeloid leukemia (AML). The MRD results after cycle 1 are highly concordant with MRD status after cycle 2. Using MRD-MFC to guide consolidation treatment can safely reduce the number of allogeneic donor searches and decrease costs.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Alessandra Sperotto, Maria Teresa Bochicchio, Giorgia Simonetti, Francesco Buccisano, Jacopo Peccatori, Simona Piemontese, Elisabetta Calistri, Giulia Ciotti, Elisabetta Pierdomenico, Roberta De Marchi, Fabio Ciceri, Michele Gottardi
Summary: Acute myeloid leukemias (AML) consist of multiple subclones that evolve by acquiring additional somatic mutations during the disease progression. The complexity and heterogeneity of AML clone architecture explain the high relapse rate among patients in hematological remission. Monitoring measurable residual disease in AML is challenging due to the difficulty in detecting genetic mutations arising during treatment. Allogeneic hematopoietic stem cell transplant has a prolonged immunological effect that can prevent relapse. Next-generation sequencing can optimize treatment outcome by monitoring measurable residual disease and clonal evolution in AML patients, especially during the transplant phase.
Review
Oncology
Tadeusz Robak, Pawel Robak
Summary: Hairy cell leukemia (HCL) is a rare type of chronic lymphoid leukemia diagnosed using cytology and multiparametric flow cytometry. Measurable residual disease (MRD) can help improve long-term outcomes in patients with advanced HCL.
FRONTIERS IN ONCOLOGY
(2022)
Article
Hematology
Corentin Orvain, Jacob A. Wilson, Min Fang, Brenda M. Sandmaier, Eduardo Rodriguez-Arboli, Brent L. Wood, Megan Othus, Frederick R. Appelbaum, Roland B. Walter
Summary: Measurable residual disease (MRD) before hematopoietic cell transplantation (HCT) is an independent prognostic factor for acute myeloid leukemia (AML) patients. The combination of residual cytogenetic abnormalities and MRD testing by multiparameter flow cytometry (MFC) improves risk assessment before HCT and provides complementary prognostic information for post-HCT outcomes in patients with cytogenetically abnormal AML undergoing allogeneic HCT.
Article
Oncology
Corentin Orvain, Megan Othus, Gurleen Johal, Mathilde Hunault-Berger, Frederick R. Appelbaum, Roland B. Walter
Summary: This study analyzed phase three randomized controlled trials (RCTs) testing non-transplant therapies for adults with acute myeloid leukemia (AML), finding high non-enrollment rates and increasingly restrictive eligibility criteria, which may limit the generalizability of results.
Article
Oncology
Christophe Desprez, Jeremie Riou, Pierre Peterlin, Tony Marchand, Marie-Anne Couturier, Alban Villate, Jean-Baptiste Mear, Patrice Chevalier, Gaelle Guillerm, Emmanuel Gyan, Aline Schmidt-Tanguy, Roland B. Walter, Mathilde Hunault-Berger, Corentin Orvain
Summary: This study compared the performance of various scoring systems in predicting mortality and survival in acute myeloid leukemia patients. The results showed that the accuracy of these scoring systems was relatively limited in identifying patients at increased risk of early mortality and shortened survival after intensive AML therapy.
Letter
Oncology
Megan Othus, Ian Thomas, Xu Wang, Cono Ariti, Priyanka Mehta, Mia Sydenham, Robert K. Hills, Alan K. Burnett, Sucha Nand, Sarit Assouline, Laura C. Michaelis, Harry P. Erba, Nigel Russell, Kathleen F. Kerr, Roland B. Walter, Mike Dennis
LEUKEMIA & LYMPHOMA
(2023)
Article
Biophysics
Roland B. Walter, Brenda M. Sandmaier, Megan Othus, Corentin Orvain, Eduardo Rodriguez-Arboli, Masumi U. Oshima, Gary Schoch, Chris Davis, H. Joachim Deeg, Rainer Storb
Summary: Reduced intensity conditioning (RIC) and nonmyeloablative (NMA) conditioning regimens are viable options for allogeneic hematopoietic cell transplantation (HCT) in AML patients. However, the relative efficacies and toxicities of these regimens are not well-defined. This study compared outcomes between RIC and NMA HCT patients and found no significant differences in relapse risk, relapse-free survival, overall survival, and non-relapse mortality. These findings suggest that the choice between RIC and NMA conditioning may not significantly impact outcomes in AML patients undergoing allografting.
BONE MARROW TRANSPLANTATION
(2023)
Review
Hematology
James S. Blachly, Roland B. Walter, Christopher S. Hourigan
Summary: Considerable progress has been made in the scientific understanding and treatment of acute myeloid leukemia. However, further research is needed to determine and improve the methods for detecting measurable residual disease.
Article
Oncology
Gabrielle Paras, Megan Othus, Kelda Schonhoff, Carole Shaw, Mohamed Sorror, Anna B. Halpern, Jacob Appelbaum, Paul Hendrie, Roland B. Walter, Elihu H. Estey, Mary-Elizabeth M. Percival
Letter
Oncology
Sarit Assouline, Laura C. Michaelis, Megan Othus, Annette E. Hay, Roland B. Walter, Meagan A. Jacoby, Mark A. Schroeder, Geoffrey L. Uy, Lisa Y. Law, Faisal Cheema, Kendra L. Sweet, Adam S. Asch, Jijun (Jane) Liu, Anna B. Moseley, Tracy Maher, Laura L. Kingsbury, Min Fang, Jerald Radich, Richard F. Little, Harry P. Erba
LEUKEMIA & LYMPHOMA
(2023)
Article
Oncology
Corentin Orvain, Eduardo Rodriguez-Arboli, Megan Othus, Brenda M. Sandmaier, H. Joachim Deeg, Frederick R. Appelbaum, Roland B. Walter
Summary: This study retrospectively analyzed 739 patients with de novo AML, 125 with antecedent hematologic disorder (AHD)/AML, and 115 with therapy-related AML who received allografts while in first or second remission. The results showed that relative to patients with de novo AML, relapse rates were similar for patients with AHD and therapy-related AML after multivariable adjustment, as were relapse-free survival and overall survival. Non-relapse mortality was higher for AHD AML. These findings suggest that the clinical history by itself has limited prognostic value for AML patients undergoing allografting.
Editorial Material
Oncology
Raffaele Palmieri, Luca Maurillo, Maria Ilaria Del Principe, Giovangiacinto Paterno, Roland Bruno Walter, Adriano Venditti, Francesco Buccisano
Article
Oncology
Michelle Y. Y. Zhang, Megan Othus, Carole Shaw, Kelda G. G. Schonhoff, Anna B. B. Halpern, Jacob Appelbaum, Paul C. C. Hendrie, Roland B. B. Walter, Elihu H. H. Estey, Mary-Elizabeth M. Percival
Summary: Patients with acute myeloid leukemia (AML) who have previously received hypomethylating agents (HMA) have a poor prognosis. High intensity induction chemotherapy may improve outcomes in these patients.
LEUKEMIA & LYMPHOMA
(2023)
Letter
Oncology
Noam E. Kopmar, Ted Gooley, Niall Curley, Kathryn Russell, Carole Shaw, Kelda Schonhoff, John Lim, Anna B. Halpern, Roland B. Walter, Bart L. Scott, Jacob Appelbaum, Paul C. Hendrie, Elihu H. Estey, Mary-Elizabeth M. Percival
LEUKEMIA & LYMPHOMA
(2023)
Letter
Oncology
Lauren Shih, Megan Othus, Kelda Schonhoff, Carole Shaw, Jacob Appelbaum, Anna B. Halpern, Pamela S. Becker, Roland B. Walter, Elihu Estey, Mary-Elizabeth Percival
Meeting Abstract
Oncology
Naveen Pammaraju, Hagop Kantarjian, Kendra Sweet, Eunice S. Wang, Andrew A. Lane, Haris Ali, Anthony S. Stein, Abdulraheem Yacoub, David Rizzieri, Sumithira Vasu, Vikas Gupta, Sangmin Lee, Gary J. Schiller, James M. Foran, Minakshi S. Taparia, Todd L. Rosenblat, Roland B. Walter, Deborah Sieminski, Madhu Anant, Mrinal M. Patnaik, Tariq I. Mughal, Marina Konopleva
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2022)
Article
Hematology
Corentin Orvain, Mariia Byelykh, Megan Othus, Brenda M. Sandmaier, Gary Schoch, Chris Davis, Frederick R. Appelbaum, Roland B. Walter
Summary: Pretransplantation nutritional status may affect the outcome of hematopoietic cell transplantation. In this study, the Nutrition Risk Index (NRI) and serum albumin level were found to be associated with post-transplant survival and relapse in AML patients. The predictive ability of NRI was relatively low and comparable to serum albumin.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)